NATEGLINIDE

Post-LOE

nateglinide

PharmaIN

ANDAORALTABLET

Approved

Sep 2009

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

NATEGLINIDE (nateglinide) by PharmaIN is potassium channel antagonists [moa]. First approved in 2009.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

Potassium Channel Antagonists

Pharmacologic Class:

Glinide

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (12)

NCT02088918Phase 1Completed

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Started Oct 2012

40 enrolled

Healthy Volunteers

NCT01316107Phase 3Completed

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Started Jan 2011

122 enrolled

Type 2 Diabetes Mellitus

NCT01030952Phase 4Completed

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Started Dec 2009

103 enrolled

Diabetes Mellitus, Type 2

NCT00928889Phase 4Completed

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

Started Jul 2009

160 enrolled

Diabetes Mellitus, Type 2

NCT01159158Phase 1Completed

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition

Started Feb 2007

68 enrolled

Healthy

Worked on NATEGLINIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.